The effectiveness of an anticoagulant in stroke has been proven
The FDA has approved the anticoagulant Brilinta for use in patients with cardiovascular disease.
A previous study involved 11,000 patients with acute ischemic stroke or transient ischemic attack has evaluated the use of aspirin with Brilinta versus aspirin alone.
According to THALES results, the first regimen reduced the risk of recurrent stroke and death by 17%. According to this, the risk of developing severe bleeding was 0.5% compared to 0.1% in the control group. The manufacturers claim that the anticoagulant Brilinta has the potential to enter the acute ischemic stroke market. Brilinta is also approved for use in reducing the risk of death from cardiovascular disease, myocardial infarction and acute coronary syndrome.